Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.63M | 1.86M | 3.07M | 6.77M | 1.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.63M | 1.86M | 3.07M | 6.77M | 1.93M |
| Cost of Revenue | 29.14M | 17.14M | 34.65M | 34.60M | 32.14M |
| Gross Profit | -27.51M | -15.28M | -31.58M | -27.83M | -30.21M |
| SG&A Expenses | 13.77M | 31.73M | 20.80M | 17.25M | 20.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.91M | 48.87M | 55.45M | 51.86M | 52.99M |
| Operating Income | -41.28M | -47.01M | -52.38M | -45.08M | -51.07M |
| Income Before Tax | -37.62M | -52.15M | -47.68M | -38.43M | -48.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.62M | -52.15M | -47.68M | -38.43M | -48.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.62M | -52.15M | -47.68M | -38.43M | -48.00M |
| EBIT | -41.28M | -47.01M | -52.38M | -45.08M | -51.07M |
| EBITDA | -37.95M | -42.20M | -47.77M | -40.36M | -46.25M |
| EPS Basic | -0.32 | -0.44 | -0.40 | -0.33 | -0.47 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.25 | -0.20 | -0.30 |
| EPS Diluted | -0.32 | -0.44 | -0.40 | -0.33 | -0.47 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.25 | -0.20 | -0.30 |
| Average Basic Shares Outstanding | 118.38M | 117.79M | 117.77M | 117.47M | 101.10M |
| Average Diluted Shares Outstanding | 118.38M | 117.79M | 117.77M | 117.47M | 101.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |